Trend
DailyDowntrend (confirmed)
4 hourAscending Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $25.79
Key levels
Support$35.75
Support$32.44
Latest news & SEC filings
AnalystHC Wainwright Keeps Buy Rating and $37 Target on SpyGlass Pharma
AnalystHC Wainwright Reaffirms Buy Rating on SpyGlass Pharma, $37 Target
ProductSpyGlass Pharma Touts Encouraging Results at Four Years for BIM-IOL Eye Implant
All SGP news →SpyGlass Pharma is a clinical-stage biopharmaceutical company developing long-acting drug delivery systems for chronic eye conditions. Its most advanced program pairs drug pads with an intraocular lens to release bimatoprost during cataract surgery for patients with open-angle glaucoma or ocular hypertension. The company is also developing a ring-shaped implant for standalone use and retreatment. It operates in the United States and retains worldwide development and commercialization rights.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$37.00
SEPT Mid Target
$37.00
SEPT High Target
$39.00
Analyst Consensus
$37.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SGP.
Start Free Trial →Valuation Verdict
FAIR
Methods Used
Analyst Consensus
Fair Value
$37.00
17
Moat Score
NONE
4/9
Piotroski Score
3.1
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-10.24%
FCF Growth YoY
-39.4%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for SGP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:01:20 | $36.12 | 2,000 | $$72K | MIDPOINT |
| 14:51:59 | $34.35 | 5,625 | $$193K | SELL |
| 21:02:54 | $34.08 | 6,338 | $$216K | SELL |
| 20:50:10 | $34.42 | 1,300 | $$45K | SELL |
| 20:42:16 | $33.86 | 1,000 | $$34K | BUY |
5 dark pool trades shown · $$560K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for SpyGlass Pharma, Inc. (SGP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SpyGlass Pharma, Inc. (SGP) is at $36.95, up 8.41% (+$2.87) at the Nov 6, 2026 close.
Latest SGP news — Oct 22, 2026: HC Wainwright Keeps Buy Rating and $37 Target on SpyGlass Pharma · Oct 21, 2026: HC Wainwright Reaffirms Buy Rating on SpyGlass Pharma, $37 Target
The average analyst price target for SGP is $37.00, ranging from $37 to $39, based on 3 analysts. Latest: HC Wainwright & Co. maintains on Oct 22, 2026.
Analyst ratings for SGP: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
SGP last reported on Aug 6, 2026: EPS -$0.59 vs -$0.51 expected — a miss of 14.7%.
Support: $35.75, $32.44, $29.96.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Oct 22, 2026: HC Wainwright Keeps Buy Rating and $37 Target on SpyGlass Pharma · Oct 21, 2026: HC Wainwright Reaffirms Buy Rating on SpyGlass Pharma, $37 Target · Oct 19, 2026: SpyGlass Pharma Touts Encouraging Results at Four Years for BIM-IOL Eye Implant